Your session is about to expire
← Back to Search
Sonelokimab (M1095) for Hidradenitis Suppurativa
Study Summary
This trial will show if a new medication is effective and safe for people with a skin condition called hidradenitis suppurativa.
- Hidradenitis Suppurativa
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 4 trial • 50 Patients • NCT01644396Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are allergic to sonelokimab or any substances used to make it.You have previously tried antibiotics to treat your hidradenitis suppurativa, but they did not work or caused side effects.You have been diagnosed with hidradenitis suppurativa by a doctor and have experienced symptoms for at least 6 months before the screening visit.You have a minimum age of 18 years.You have another ongoing skin condition that might affect the evaluation of your hidradenitis suppurativa.You have tried antibiotics to treat your hidradenitis suppurativa but they did not work or you cannot take them due to side effects or other reasons.You have already used more than 2 different types of biologic medications.You are allergic to adalimumab or any of its ingredients.You have been diagnosed with either ulcerative colitis or Crohn's disease.You have a total abscess and/or inflammatory nodule (AN) count of ≥5.You have been diagnosed with a skin condition called hidradenitis suppurativa, and have had symptoms for at least 6 months before the screening visit.
- Group 1: sonelokimab dose 2
- Group 2: Placebo
- Group 3: adalimumab
- Group 4: sonelokimab dose 1
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What severe adverse effects have been linked with Sonelokimab (M1095) use?
"While Phase 2 trials do not have the same level of efficacy data, Sonelokimab (M1095) has been determined to be safe."
How many people are being given the opportunity to participate in this clinical trial?
"The answer is affirmative, active recruitment is taking place for this clinical trial according to the information on clinicaltrials.gov. This specific study was initially posted on April 25th, 2022 and updated November 7th of the same year. The total number of patients needed for participation is 210, recruited from 33 different sites."
Are there any available positions for patients in this clinical trial?
"Yes, the trial is currently ongoing. According to the listing on clinicaltrials.gov, it was posted on 4/25/2022 and last edited on 11/7/2022. They are looking for a total of 210 patients from 33 different sites."
Is this research study also taking place in other states besides the one where it began?
"This particular clinical trial has 33 enrollment sites which are situated in Markham, Beverly, Fredericton, and 30 other cities. To limit travel-related inconveniences, it is recommended that you choose a location near to you."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger